Turning the Tide: Applying Science to Patient Care in Treating Psoriasis, Psoriatic Arthritis, and Atopic Dermatitis
Fast-paced and focused on emerging science and treatment techniques, Turning the Tide is an interactive activity designed to sharpen participants’ understanding of psoriasis, psoriatic arthritis, and atopic dermatitis and equip them with forward-thinking patient-centered communication strategies. Through a combination of medical animation, TED Talks-style presentations, a clinical case study, and a discussion of patient-provider shared decision making, learners will explore disease pathophysiology, mechanisms of action of targeted therapies, evidence-based treatment recommendations, and use of decision aids. Learners will be provided access to slides and additional resources.
-
Bruce Strober, MD, PhD
Professor,
Department of Dermatology
University of Connecticut Health Center
Farmington, Connecticut
-
Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
East Lansing, Michigan
Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
Planners (Forefront Collaborative)
- Christine Tebben
- Marianna Shershneva, MD, PhD
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Presenter: Bruce Strober, MD, PhD
- Consultant (honoraria): AbbVie, Almirall, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, GlaxoSmithKline, Janssen, LEO Pharma, Lilly, Medac, Meiji Seika Pharma, Menlo Therapeutics, Novartis, Ortho Dermatologics/Valeant, Pfizer, Regeneron, Sanofi Genzyme, Sebela Pharmaceuticals, Sitris, Sun Pharma, UCB
- Investigator (no direct payments made to Bruce Strober, MD, PhD): AbbVie, Boehringer Ingelheim, Celgene, Galderma, GlaxoSmithKline, Janssen, Lilly, Merck, Pfizer, Sienna Biopharmaceuticals
- Scientific Director (consulting fee): Corrona/NPF Psoriasis Registry
- Grant support for Fellowship Program (payments to the University of Connecticut): AbbVie, Janssen, National Psoriasis Foundation
Presenter: Richard Martin, MD, MA, has contracted research for AbbVie, Amgen, AstraZeneca, Lilly, and Cytori
Planner: April W. Armstrong MD, MPH, is a consultant for AbbVie, Janssen, Lilly, Pfizer, Ortho Dermatologics, Sanofi Genzyme, Regeneron, Bristol-Myers Squibb, Dermavant, Science 37, Modernizing Medicine, LEO Pharma, Novartis; researcher for Janssen, Lilly, UCB Biopharma, Dermira, Bristol-Myers Squibb, LEO Pharma, Novartis, Kyowa Hakko Kirin
As a result of participation in this educational activity, participants should increase their ability to:
-
Describe current models explaining pathophysiology of psoriasis and atopic dermatitis
-
Identify mechanisms of action and effectiveness of existing and emerging targeted treatments for psoriasis and atopic dermatitis
-
Discuss evolving treatment strategies and safety of treatments for psoriasis, psoriatic arthritis, and atopic dermatitis
-
Engage patients with psoriatic disease or atopic dermatitis in shared decision-making regarding goals of treatment, development of treatment plan, and treatment modification
Resources
Unless otherwise specifically prohibited, you may temporarily download one copy of the materials for personal, noncommercial use. You may not modify or copy the materials, use them for any commercial purpose or public display (commercial or noncommercial), remove any copyright or other proprietary notations, or transfer the materials to another person or online site.
Target Audience
The target audience is dermatologists. Other healthcare professionals, including rheumatologists, physician assistants, and nurse practitioners who treat patients with psoriasis, PsA, and AD, may benefit from participation in this educational activity.
Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Forefront Collaborative designated this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Content Review
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity included reference(s) to unlabeled or unapproved uses of drugs.
The views and opinions expressed in this activity are those of the faculty and did not necessarily reflect the views or recommendations of Forefront Collaborative.
Provider
This activity is provided by Forefront Collaborative.
Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.